Mott MacDonald is delivering the project with BSAC
For Antibiotic Awareness Week 2019 Mott MacDonald has shared information on the first feedback workshop assessing the Antimicrobial Resistance (AMR) risk in hospitals in Georgia. The workshop was led by Professor Dilip Nathwani, chair of the British Society for Antimicrobial Chemotherapy (BSAC), and was held in Tbilisi in last month.
The project is being funded by the European Bank for Reconstruction and Development (EBRD). Mott MacDonald is delivering the project with BSAC.
The project examines the impact of the Private-Public Partnership model on the emergence and containment of drug resistant bacterial infections, which is now a global healthcare priority. Conservative estimates indicate that in Europe, 25,000 people die each year due to drug resistant infections: globally this may be up to 700,000 people each year. It is therefore vital that any new investment in healthcare provision ensures that structures and strategies are in place to minimise the emergence and transmission of resistant infections. The assessments on AMR involve five sites in Georgia and Turkey, managed by three different private service providers.
Mott MacDonald is the management agent for the programme, working for the EBRD. This work includes assessing provision of clinical support services, reviewing hospital policies for antimicrobial prescribing and infection prevention and control, observing compliance with policies and guidelines, and reviewing laboratory capacity for the diagnosis of bacterial infections. Following site visits, recommendations are made to the stakeholders and an interactive feedback workshop held to provide guidance for developing ongoing programmes of improvement in AMR risk areas. The project utilises in-house, national and international experts in AMR, Infection Prevention and Control and Antimicrobial Stewardship.
Mott MacDonald’s project principal for Georgia, Dr Claire Gordon, said: “It is fantastic to see the first feedback workshop on this project to combat AMR. We look forward to continuing to support stakeholders to develop in-house programmes tailored to their own needs.”
The pilot phase of this project will end in December 2019.